Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.

NCT05311943 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Olverembatinib
Chronic Myeloid Leukemia, Chronic Phase
Tyrosine Kinase Inhibitors

Interventions

DRUG: olverembatinib

Sponsor

Shenzhen Second People's Hospital